drugset / Trial / NCT03296618

Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke

NCT03296618 ↗

Phase 1 Unknown 18 enrolled Suzhou Neuralstem Biopharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The study is to determine the safety of human neural stem cell transplantation for the treatment of paralysis and related symptoms due to chronic motor stroke and to determine the maximum tolerated dose.

Timeline

Start
2012-06
Primary completion
2018-05
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject NSI-566 Cell therapy 1.2e+07 cells Other
Subject NSI-566 Cell therapy 8e+07 cells Other

Indications